Neuroimaging analyses from a randomized, controlled study to evaluate plasma exchange with albumin replacement in mild-to-moderate Alzheimer’s disease: additional results from the AMBAR study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1619-7089
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Neuroimaging analyses from a randomized, controlled study to evaluate plasma exchange with albumin replacement in mild-to-moderate Alzheimer’s disease: additional results from the AMBAR study ; day:22 ; month:7 ; year:2022 ; pages:1-12
European journal of nuclear medicine and molecular imaging ; (22.7.2022), 1-12
- Creator
-
Cuberas-Borrós, Gemma
Roca, Isabel
Castell-Conesa, Joan
Núñez, Laura
Boada, Mercè
López, Oscar L.
Grifols, Carlota
Barceló, Miquel
Pareto, Deborah
Páez, Antonio
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00259-022-05915-5
- URN
-
urn:nbn:de:101:1-2022100319205275801003
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:32 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Cuberas-Borrós, Gemma
- Roca, Isabel
- Castell-Conesa, Joan
- Núñez, Laura
- Boada, Mercè
- López, Oscar L.
- Grifols, Carlota
- Barceló, Miquel
- Pareto, Deborah
- Páez, Antonio
- SpringerLink (Online service)
Other Objects (12)
Dysphagia is closely related to frailty in mild-to-moderate Alzheimer’s disease
Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
Estimating attrition in mild-to-moderate Alzheimer’s disease and mild cognitive impairment clinical trials
A 12-month randomised pilot trial of the Alzheimer’s and music therapy study: a feasibility assessment of music therapy and physical activity in patients with mild-to-moderate Alzheimer’s disease
Molecular Dynamics Simulation: Applications from Alzheimer’s Disease to Photopharmacology
Alzheimer’s disease prevention: from risk factors to early intervention
Cellular senescence in Alzheimer’s disease: from physiology to pathology
NeuroEPO plus (NeuralCIM®) in mild-to-moderate Alzheimer’s clinical syndrome: the ATHENEA randomized clinical trial
Effectiveness of the 10 cm2 Rivastigmine Patch in Taiwanese Patients with Mild-to-Moderate Alzheimer’s Dementia: A 48-Week Real-World Observational Study
Alzheimer disease : from molecular biology to therapy
Cohort Effects in Alzheimer’s Disease Trials: An Empirical Assessment Utilizing Data from the Alzheimer’s Disease Cooperative Study
Dysphagia is closely related to frailty in mild-to-moderate Alzheimer’s disease
Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
Estimating attrition in mild-to-moderate Alzheimer’s disease and mild cognitive impairment clinical trials
A 12-month randomised pilot trial of the Alzheimer’s and music therapy study: a feasibility assessment of music therapy and physical activity in patients with mild-to-moderate Alzheimer’s disease
Molecular Dynamics Simulation: Applications from Alzheimer’s Disease to Photopharmacology
Alzheimer’s disease prevention: from risk factors to early intervention
Cellular senescence in Alzheimer’s disease: from physiology to pathology
NeuroEPO plus (NeuralCIM®) in mild-to-moderate Alzheimer’s clinical syndrome: the ATHENEA randomized clinical trial
Effectiveness of the 10 cm2 Rivastigmine Patch in Taiwanese Patients with Mild-to-Moderate Alzheimer’s Dementia: A 48-Week Real-World Observational Study
Alzheimer disease : from molecular biology to therapy
Cohort Effects in Alzheimer’s Disease Trials: An Empirical Assessment Utilizing Data from the Alzheimer’s Disease Cooperative Study
Dysphagia is closely related to frailty in mild-to-moderate Alzheimer’s disease
Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
Estimating attrition in mild-to-moderate Alzheimer’s disease and mild cognitive impairment clinical trials
A 12-month randomised pilot trial of the Alzheimer’s and music therapy study: a feasibility assessment of music therapy and physical activity in patients with mild-to-moderate Alzheimer’s disease
Molecular Dynamics Simulation: Applications from Alzheimer’s Disease to Photopharmacology
Alzheimer’s disease prevention: from risk factors to early intervention
Cellular senescence in Alzheimer’s disease: from physiology to pathology
NeuroEPO plus (NeuralCIM®) in mild-to-moderate Alzheimer’s clinical syndrome: the ATHENEA randomized clinical trial
Effectiveness of the 10 cm2 Rivastigmine Patch in Taiwanese Patients with Mild-to-Moderate Alzheimer’s Dementia: A 48-Week Real-World Observational Study
Alzheimer disease : from molecular biology to therapy